Physician profile
Linda H Trinh
NPI 1124333828
$883,785.29
in general payments reported to CMS, 2019-2025
45 companies · $205K in 2025
The $205K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81K · 2022: $187K · 2023: $211K · 2024: $199K · 2025: $205K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $458K · Travel and Lodging: $80K · Consulting Fee: $51K · Food and Beverage: $26K · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $458,179.60 |
| Travel and Lodging | $80,358.57 |
| Consulting Fee | $50,796.00 |
| Food and Beverage | $26,105.84 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $328,325.12 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $231,474.96 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $175,093.13 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $66,286.92 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $38,393.67 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $20,206.54 | 2024-2025 | Cobenfy |
| Biogen, INC. | $10,810.76 | 2021-2024 | |
| Sage Therapeutics, LLC | $2,680.21 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,975.33 | 2021-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,283.74 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,245.07 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $701.59 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $520.61 | 2022-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $519.14 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $481.72 | 2021-2025 | Rexulti |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Trinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.